Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Momenta Stopped

The good news is that, after 26 months of having an abbreviated new drug application (ANDA) sitting in the FDA's Office of Generic Drugs, Momenta Pharmaceuticals (Nasdaq: MNTA  ) and Novartis (NYSE: NVS  ) finally have a decision on their generic version of Sanofi-Aventis' (NYSE: SNY  ) Lovenox. The bad news was that it was in the form of a not-approvable letter.

With no prior warning, the FDA shot down the application because the agency is worried that the drug might cause an immune reaction. Without a mechanism in place to hand out an approvable letter like it would with an NDA, the office had no other choice but to issue the not-approvable letter. It's possible that the duo could amend its ANDA, so it won't have to reset the review clock.

Unless they were smart enough to address the issue in their application, Teva Pharmaceuticals (Nasdaq: TEVA  ) and Amphastar should expect a not-approvable letter in their mailboxes soon, too. Momenta reports that the FDA told it that all companies developing generic versions of Lovenox will have to address the potential for immunogenicity of the drug.

At this point, Momenta doesn't have much information about what the FDA will require to prove the lack of immunogenicity. The possibilities range from a PubMed search of the literature (a delay of a few weeks) to animal studies (a delay of a month or two) to clinical trials (a delay of six months or more). Until the companies meet with the FDA, everyone -- sans the agency -- is in the dark as to exactly what will be expected. Looks like Newton's first law of motion will apply and Momenta will remain at rest until it receives some momentum from the FDA.

That lack of information is what spurred the more than 50% drop in Momenta's stock price yesterday. There's clearly upside potential at this price if the delay is minor, but without more knowledge, buying the stock at this point is more akin to gambling than investing.

More Foolishness on Momenta:

Read/Post Comments (0) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 539835, ~/Articles/ArticleHandler.aspx, 10/25/2016 12:16:47 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,182.69 -40.34 -0.22%
S&P 500 2,144.48 -6.85 -0.32%
NASD 5,287.59 -22.23 -0.42%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/25/2016 11:58 AM
MNTA $11.88 Up +0.01 +0.04%
Momenta Pharmaceut… CAPS Rating: ****
NVS $72.93 Down -2.52 -3.34%
Novartis CAPS Rating: ****
SNY $37.38 Down -0.38 -1.01%
Sanofi CAPS Rating: *****
TEVA $44.03 Up +0.53 +1.22%
Teva Pharmaceutica… CAPS Rating: ****